JP7758687B2 - 神経筋疾患の処置のためのピリダジノン化合物 - Google Patents
神経筋疾患の処置のためのピリダジノン化合物Info
- Publication number
- JP7758687B2 JP7758687B2 JP2022568792A JP2022568792A JP7758687B2 JP 7758687 B2 JP7758687 B2 JP 7758687B2 JP 2022568792 A JP2022568792 A JP 2022568792A JP 2022568792 A JP2022568792 A JP 2022568792A JP 7758687 B2 JP7758687 B2 JP 7758687B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- halogen
- compound
- carbocycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063024442P | 2020-05-13 | 2020-05-13 | |
| US63/024,442 | 2020-05-13 | ||
| PCT/US2021/031989 WO2021231572A1 (en) | 2020-05-13 | 2021-05-12 | Pyridazinone compounds for the treatment of neuromuscular diseases |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023526247A JP2023526247A (ja) | 2023-06-21 |
| JP2023526247A5 JP2023526247A5 (https=) | 2024-05-22 |
| JPWO2021231572A5 JPWO2021231572A5 (https=) | 2024-05-22 |
| JP7758687B2 true JP7758687B2 (ja) | 2025-10-22 |
Family
ID=76444536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568792A Active JP7758687B2 (ja) | 2020-05-13 | 2021-05-12 | 神経筋疾患の処置のためのピリダジノン化合物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230150977A1 (https=) |
| EP (1) | EP4149621B1 (https=) |
| JP (1) | JP7758687B2 (https=) |
| WO (1) | WO2021231572A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3877376T3 (da) | 2018-11-06 | 2023-10-02 | Edgewise Therapeutics Inc | Pyridazinonforbindelser og anvendelser deraf |
| CA3118908A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| AU2019374812B2 (en) | 2018-11-06 | 2025-03-06 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| CN120302976A (zh) | 2022-09-09 | 2025-07-11 | 艾知怀斯治疗学公司 | 用于治疗神经肌肉病状的哒嗪酮组合物 |
| KR20250121977A (ko) * | 2023-01-04 | 2025-08-12 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | 피리다지논 헤테로사이클릭 화합물 Myosin II 억제제 및 이의 용도 |
| WO2025153721A1 (en) * | 2024-01-19 | 2025-07-24 | Scenic Biotech Bv | Pla2g15 inhibitors |
| WO2025167826A1 (zh) * | 2024-02-06 | 2025-08-14 | 西藏海思科制药有限公司 | 三环化合物作为Myosin II抑制剂及其用途 |
| WO2025175141A1 (en) * | 2024-02-16 | 2025-08-21 | Cytokinetics, Incorporated | Fast skeletal muscle myosin inhibitors |
| WO2025242154A1 (zh) * | 2024-05-23 | 2025-11-27 | 西藏海思科制药有限公司 | 哒嗪酮衍生物及其用途 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003535850A (ja) | 2000-06-05 | 2003-12-02 | アルタナ ファルマ アクチエンゲゼルシャフト | β−２−アドレナリン受容体として効果的な化合物並びにＰＤＥ４−インヒビター |
| WO2008013838A2 (en) | 2006-07-25 | 2008-01-31 | Cephalon, Inc. | Pyridizinone derivatives |
| JP2010519204A (ja) | 2007-02-16 | 2010-06-03 | アムジエン・インコーポレーテツド | 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用 |
| US20120289698A1 (en) | 2011-04-22 | 2012-11-15 | Ashcraft Luke W | Certain heterocycles, compositions thereof, and methods for their use |
| JP2013525377A (ja) | 2010-04-23 | 2013-06-20 | サイトキネティクス・インコーポレーテッド | ある種のアミノ−ピリミジン、その組成物、及びそれを用いるための方法 |
| WO2019084499A1 (en) | 2017-10-27 | 2019-05-02 | Genea Biocells USA (Holdings), Inc. | INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION |
| WO2019236625A1 (en) | 2018-06-04 | 2019-12-12 | Ohio State Innovation Foundation | Eaat2 activators and methods of using thereof |
| JP2020512364A (ja) | 2017-03-28 | 2020-04-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 筋ジストロフィーの処置方法において使用するためのニンテダニブ |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CN1087725C (zh) | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| CA3118908A1 (en) * | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| AU2019374812B2 (en) * | 2018-11-06 | 2025-03-06 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| DK3877376T3 (da) * | 2018-11-06 | 2023-10-02 | Edgewise Therapeutics Inc | Pyridazinonforbindelser og anvendelser deraf |
-
2021
- 2021-05-12 EP EP21732618.0A patent/EP4149621B1/en active Active
- 2021-05-12 WO PCT/US2021/031989 patent/WO2021231572A1/en not_active Ceased
- 2021-05-12 JP JP2022568792A patent/JP7758687B2/ja active Active
-
2022
- 2022-11-07 US US18/053,326 patent/US20230150977A1/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003535850A (ja) | 2000-06-05 | 2003-12-02 | アルタナ ファルマ アクチエンゲゼルシャフト | β−２−アドレナリン受容体として効果的な化合物並びにＰＤＥ４−インヒビター |
| WO2008013838A2 (en) | 2006-07-25 | 2008-01-31 | Cephalon, Inc. | Pyridizinone derivatives |
| JP2010519204A (ja) | 2007-02-16 | 2010-06-03 | アムジエン・インコーポレーテツド | 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用 |
| JP2013525377A (ja) | 2010-04-23 | 2013-06-20 | サイトキネティクス・インコーポレーテッド | ある種のアミノ−ピリミジン、その組成物、及びそれを用いるための方法 |
| US20120289698A1 (en) | 2011-04-22 | 2012-11-15 | Ashcraft Luke W | Certain heterocycles, compositions thereof, and methods for their use |
| JP2020512364A (ja) | 2017-03-28 | 2020-04-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 筋ジストロフィーの処置方法において使用するためのニンテダニブ |
| WO2019084499A1 (en) | 2017-10-27 | 2019-05-02 | Genea Biocells USA (Holdings), Inc. | INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION |
| WO2019236625A1 (en) | 2018-06-04 | 2019-12-12 | Ohio State Innovation Foundation | Eaat2 activators and methods of using thereof |
Non-Patent Citations (2)
| Title |
|---|
| Hudkins, Robert L. et al.，Discovery and Characterization of 6-{4-[3-(R)-2-Methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, Irdabisant): A Potent, Selective Histamine H3 Receptor Inverse Agonist，Journal of Medicinal Chemistry，2011年，Vol.54(13)，p.4781-4792 |
| McKinstry-Wu et al.，Discovery of a Novel General Anesthetic Chemotype Using High-throughput Screening，Anesthesiology，2015年，Vol.122(2)，p.325-333 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023526247A (ja) | 2023-06-21 |
| WO2021231572A1 (en) | 2021-11-18 |
| US20230150977A1 (en) | 2023-05-18 |
| EP4149621A1 (en) | 2023-03-22 |
| EP4149621B1 (en) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7758687B2 (ja) | 神経筋疾患の処置のためのピリダジノン化合物 | |
| JP7715911B2 (ja) | 神経筋疾患の処置のためのピリダジノン化合物 | |
| JP7357135B2 (ja) | ピリダジノン化合物およびその使用 | |
| US12240833B2 (en) | Pyridazinone compounds and uses thereof | |
| US20230293518A1 (en) | Substituted pyridazinones for use in the treatment of neuromuscular diseases | |
| JP7429750B2 (ja) | ピリダジノン化合物およびその使用 | |
| US20230338375A1 (en) | Substituted pyridazinones for use in the treatment of neuromuscular diseases | |
| EP4149467A1 (en) | Substituted pyridazinone for use in the treatment of neuromuscular diseases | |
| WO2023091606A1 (en) | Pyridazinone compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240513 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240513 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250328 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250625 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250828 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250911 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251009 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7758687 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |